Pharma BD Deal Intelligence

Pathos AI, Inc. / Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

2026 · Licensing/Option · $2.2B · Pending

On August 3, 2026, Pathos AI entered a global licensing agreement with Alphamab Oncology (Jiangsu Alphamab Biopharmaceuticals) for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate. Pathos pays $125 million upfront and up to $2,093 million in development, regulatory and commercial milestones (up to $2,218 million total), plus tiered high-single-digit to low-double-digit royalties on aggregate annual net sales. Pathos receives exclusive rights outside Chinese Mainland, Hong Kong, Macau and Taiwan; Alphamab retains Greater China rights. JSKN016 is in an ongoing Phase 3 trial in triple-negative breast cancer. Pathos identified the asset through its AI decision platform, Foundry. NOTE: ingested at pending_review by bd-enrichment 2026-08-05.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Pathos AI, Inc. deals